Could a stronger blood thinner save trauma patients from deadly clots?

NCT ID NCT07506473

Not yet recruiting Prevention Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a higher dose of the blood thinner enoxaparin can better prevent dangerous blood clots in the legs or lungs of severely injured patients. About 540 adults in intensive care after trauma will receive either the standard or a double dose. The goal is to see if the higher dose reduces clots without increasing serious bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE TRAUMA PATIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

injury venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE TRAUMA PATIENT VENOUS THROMBOEMBOLISM

Contacts and locations

Locations

AP-HP Bicêtre

Le Kremlin-Bicêtre, 94270, France
Assistance Publique - Hôpitaux de Marseille

Marseille, 13005, France
CHRU Lille

Lille, 59000, France
CHU Angers

Angers, 49100, France
CHU Clermont Ferrand

Clermont-Ferrand, 63000, France
CHU Grenoble Alpes

Grenoble, 38000, France
CHU Montpellier

Montpellier, 34080, France
CHU Nantes

Nantes, 44000, France
CHU Rennes

Rennes, 35000, France
CHU Strasbourg

Strasbourg, 67200, France
CHU Tours

Tours, 37000, France
CHU de Toulouse

Toulouse, 31300, France
HCL Lyon Sud

Lyon, 69310, France
Hôpital Beaujon AP-HP

Clichy, 92110, France
Hôpital Edouard Herriot HCL

Lyon, 69003, France
Hôpital Européen Georges Pompidou AP-HP

Paris, 75015, France
Hôpital Pitié-Salpêtrière APHP

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.